Clinical trial
Therapeutic Monitoring of Infliximab and Adalimumab in Pediatric Chronic Inflammatory Diseases: Innovative Pharmacological Strategies for Predicting Response and Adverse Effects
NCT06033469 is registered in ClinicalTrials.gov with IRCCS Burlo Garofolo as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Therapeutic Monitoring of Infliximab and Adalimumab in Pediatric Chronic Inflammatory Diseases: Innovative Pharmacological Strategies for Predicting Response and Adverse Effects
- Lead sponsor
- IRCCS Burlo Garofolo
- Phase
- Observational
- Overall status
- Unknown status
- Start date
- March 15, 2018
- Completion date
- June 30, 2024
- Enrollment
- 100 (estimated)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.